Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma ABOSTO:EQL -1.93%42 ROC (Joel Greenblatt) % is 8.76% as of Mar. 2026, which is 80% below its 10-year median of 44.76. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 983 Drug Manufacturers companies, EQL Pharma AB ranks better than 65.72% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. EQL Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.76%.
The historical rank and industry rank for EQL Pharma AB's ROC (Joel Greenblatt) % or its related term are showing as below:
OSTO:EQL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -22.05 Med: 44.76 Max: 97.98
Current: 21.23
During the past 13 years, EQL Pharma AB's highest ROC (Joel Greenblatt) % was 97.98%. The lowest was -22.05%. And the median was 44.76%.
OSTO:EQL's ROC (Joel Greenblatt) % is ranked better than 65.72% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs OSTO:EQL: 21.23
EQL Pharma AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -16.30% per year.
EQL Pharma AB (OSTO:EQL) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
EQL Pharma AB ROC (Joel Greenblatt) % Related Terms
EQL Pharma AB ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EQL vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 8.76% mean?
EQL Pharma AB (OSTO:EQL) has a ROC (Joel Greenblatt) % of 8.76% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on EQL Pharma AB and its competitors. This is 80% below median its historical median of 44.76. According to the industry distribution chart, EQL Pharma AB ranks #337 out of 983 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is EQL Pharma AB's ROC (Joel Greenblatt) % too high?
EQL Pharma AB's current ROC (Joel Greenblatt) % of 8.76% is 80% below median its 10-year median of 44.76. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. EQL Pharma AB's value of 8.76% is 23.6% below this industry median. Based on the distribution chart, EQL Pharma AB ranks #337 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #337 out of 983 companies for ROC (Joel Greenblatt) %. This puts EQL Pharma AB in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. EQL Pharma AB's value of 8.76% is 23.6% below this benchmark. While the company's 10-year median is 44.76 vs. the industry median of 11.46, EQL Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current ROC (Joel Greenblatt) % of 8.76% is 23.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current ROC (Joel Greenblatt) % is 8.76%, which is 80% below median its own 10-year median of 44.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current ROC (Joel Greenblatt) % of 8.76%. The current ROC (Joel Greenblatt) % is 8.76%, which is 80% below median its 10-year median of 44.76 and 23.6% below the Drug Manufacturers industry median of 11.46. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current ROC (Joel Greenblatt) % is 8.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
